Turn differentiates through its oil-based delivery technology that enables biologic-level efficacy with localized delivery, avoiding systemic exposure and associated side effects. The company's business model combines a focused clinical pipeline with non-dilutive revenue through strategic partnerships, including agreements with Medline in wound care markets.
Cyborg Score Rationale
Turn exhibits promise as an early-stage biotech with an innovative delivery platform and clear clinical pathway (GX-03 Phase 2 data expected H1 2026), but faces significant risk as a newly public company with negative net income, high stock volatility (60% decline since IPO peak), and early-stage pipeline dependency.
Top Insights
GX-03 Phase 2 trial interim/topline data expected H1 2026 - critical near-term catalyst for valuation
Recently went public via direct listing (Oct 8, 2025) with stock declining 74% from peak ($26.50 Oct 2025 to ~$3.35-$4.83 current) indicating post-IPO volatility and investor wariness
PermaFusion platform offers significant competitive differentiation through stable suspension of water-soluble drugs in oil without emulsifiers, enabling targeted local delivery
Non-dilutive partnership revenue strategy (Medline, others) provides runway without immediate capital raise pressure, supported by flexible GEM Global Yield financing facility
Named Competitors
Rinvoq/Skyrizi — Systemic JAK inhibitors and biologics for dermatologic indications
Nucala — IL-5 pathway monoclonal antibody for eosinophilic conditions
Dupilumab — IL-4 pathway biologic for atopic dermatitis (systemic)
Recent Developments
(October 2025) Successfully completed direct listing on NASDAQ under ticker TTRX
(September 2025) Completed name change from Global Health Solutions, Inc. to Turn Therapeutics Inc.
(January 2026) Announced Board strengthening with appointments of Arthur Golden and Dr. Kent Kester
Open the full interactive Turn Therapeutics Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.